Clinical trial
Effect of Inhaled Nitric Oxide on Major Adverse Events Requiring Intensive Life Support in Adults Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Phase III, Double-Blind, Multicenter, Randomized Controlled Trial (Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass, the NORISC Trial)
NCT06702553 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Inhaled Nitric Oxide on Major Adverse Events Requiring Intensive Life Support in Adults Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Phase III, Double-Blind, Multicenter, Randomized Controlled Trial (Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass, the NORISC Trial)
- Lead sponsor
- Xijing Hospital
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- May 19, 2025
- Completion date
- March 31, 2029
- Enrollment
- 3,650 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
adult patients undergoing cardiovascular surgery with cardiopulmonary bypass, cardiac surgery, cardiopulmonary bypass, nitric oxide